This Investigator-Initiated Research Award (IIRA) from the Department of Defense (DoD) Gulf War Illness Research Program (GWIRP) is for supporting research focused on Gulf War Illness (GWI). Its purpose is to improve GWI definition and diagnosis, characterize symptoms, and better understand its pathobiology. The grant aims to identify objective measures like biomarkers or elucidate potential treatment targets. It also supports studies characterizing chronic effects of neurotoxic exposures. Research areas include central nervous system function, neuroinflammation, autonomic nervous system, neuroendocrine, immune, gastrointestinal, genetic, respiratory, and sexual dysfunction. The IIRA encourages new ideas in GWI research, welcoming proposals with or without preliminary data, as long as they clearly focus on ill Gulf War veterans. Clinical trials are excluded; separate mechanisms exist for those.
Opportunity ID: 90053
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-11-GWIRP-IIRA |
| Funding Opportunity Title: | DoD Gulf War Illness Investigator-Initiated Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Apr 27, 2011 |
| Last Updated Date: | Apr 28, 2011 |
| Original Closing Date for Applications: | Aug 25, 2011 |
| Current Closing Date for Applications: | Aug 24, 2011 |
| Archive Date: | Sep 24, 2011 |
| Estimated Total Program Funding: | $1,920,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The GWIRP Investigator-Initiated Research Award (IIRA) mechanism was first offered in FY06. Since then, 94 IIRA applications have been received, and 29 have been recommended for funding.The IIRA supports research focusing on the complex of symptoms known as Gulf War Illness (GWI), improving its definition and diagnosis, characterizing disease symptoms, and better understanding its pathobiology. It is intended to encourage basic or clinical developmental research aimed at identification of objective measures to distinguish ill from healthy veterans (e.g., biomarkers) or elucidate potential treatment targets for GWI. In addition, studies that characterize chronic effects of neurotoxic exposures at dosage comparable to that encountered during the Gulf War are acceptable. The IIRA provides investigators a mechanism to establish proof of principle for further development in future studies. Particular areas of interest include research on objective indicators of biological processes, or abnormalities in GWI associated with:� Central nervous system structure and function, in particular, the role of glial cells, astrocytes, and microglia in GWI symptomatology� Central neuroinflammatory processes� Autonomic nervous system function� Neuroendocrine measures� Immune parameters/Indicators of chronic infection� Gastrointestinal complaints/symptoms� Genetic, genomic, proteomic, or metabolic characteristics� Respiratory symptoms� Sexual dysfunctionThe IIRA is designed to promote new ideas in GWI research. Proposals are not required to include preliminary data; however, preliminary data may be used to support the objectives of a proposal. These data are not required to have come from the GWI research field. Proposals not supported by preliminary data should be based on a sound scientific rationale and may reflect clinical observations or seek to evaluate GWI discoveries made in relation to other chronic multi-symptom illnesses. Using either approach, however, the focus should be clearly on ill Gulf War veterans. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the project�s potential impact on GWI.PIs proposing clinical research must provide a published case definition they intend to use to define their GWI population. Any case definition must recognize the multi-symptom nature of GWI. PIs proposing studies using animal models should focus on long-term and latent effects of toxic exposures to closely represent the current status of GWI patients.NOTE: The 2008 report of the Research Advisory Committee on Gulf War Veterans� Illnesses, Gulf War Illness and the Health of Gulf War Veterans, provides information on GWI case definitions (pp. 29-30, p. 57), previous treatment research in Gulf War veterans (pp. 36-39), and treatment research related to other multi-symptom conditions (pp. 285-287). The report can be found online at: http://www1.va.gov/RAC-GWVI/.Research involving human subjects is permitted under this funding opportunity, but is restricted to studies without clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. For more information on clinical research, a Human Subject Resource Document is provided at https://cdmrp.org/Program_Announcements_and_Forms/.PIs wishing to apply for funding for a clinical trial should utilize either the Innovative Treatment Evaluation Award or the Clinical Trial Award mechanisms (for information about those mechanisms, see http://cdmrp.army.mil/gwirp). Refer to the General Application Instructions, Appendix 5, for helpful information about distinguishing clinical trials and clinical research. Retrospective studies or other non-interventional designs are acceptable under the IIRA award mechanism. Studies whose principal focus is on psychiatric disease or psychological stress as the primary cause of GWI will not be funded under this Program Announcement/Funding Opportunity.While Gulf War veterans are affected by Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig�s disease) at twice the rate of veterans who did not serve in the Gulf War, the GWIRP will not accept proposals focusing on ALS research. However, proposals that focus on GWI symptomatology may include GW veterans with ALS if the latter disorder is included in the study’s GWI case definition. The Office of the Congressionally Directed Medical Research Programs (CDMRP) has offered a separate ALS Research Program (see http://cdmrp.army.mil/alsrp). |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
301-682-5507
Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Apr 28, 2011 | ||
| Apr 28, 2011 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-11-GWIRP-IIRA |
| Funding Opportunity Title: | DoD Gulf War Illness Investigator-Initiated Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Apr 27, 2011 |
| Last Updated Date: | Apr 28, 2011 |
| Original Closing Date for Applications: | Aug 25, 2011 |
| Current Closing Date for Applications: | Aug 24, 2011 |
| Archive Date: | Sep 24, 2011 |
| Estimated Total Program Funding: | $1,920,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The GWIRP Investigator-Initiated Research Award (IIRA) mechanism was first offered in FY06. Since then, 94 IIRA applications have been received, and 29 have been recommended for funding.The IIRA supports research focusing on the complex of symptoms known as Gulf War Illness (GWI), improving its definition and diagnosis, characterizing disease symptoms, and better understanding its pathobiology. It is intended to encourage basic or clinical developmental research aimed at identification of objective measures to distinguish ill from healthy veterans (e.g., biomarkers) or elucidate potential treatment targets for GWI. In addition, studies that characterize chronic effects of neurotoxic exposures at dosage comparable to that encountered during the Gulf War are acceptable. The IIRA provides investigators a mechanism to establish proof of principle for further development in future studies. Particular areas of interest include research on objective indicators of biological processes, or abnormalities in GWI associated with:� Central nervous system structure and function, in particular, the role of glial cells, astrocytes, and microglia in GWI symptomatology� Central neuroinflammatory processes� Autonomic nervous system function� Neuroendocrine measures� Immune parameters/Indicators of chronic infection� Gastrointestinal complaints/symptoms� Genetic, genomic, proteomic, or metabolic characteristics� Respiratory symptoms� Sexual dysfunctionThe IIRA is designed to promote new ideas in GWI research. Proposals are not required to include preliminary data; however, preliminary data may be used to support the objectives of a proposal. These data are not required to have come from the GWI research field. Proposals not supported by preliminary data should be based on a sound scientific rationale and may reflect clinical observations or seek to evaluate GWI discoveries made in relation to other chronic multi-symptom illnesses. Using either approach, however, the focus should be clearly on ill Gulf War veterans. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the project�s potential impact on GWI.PIs proposing clinical research must provide a published case definition they intend to use to define their GWI population. Any case definition must recognize the multi-symptom nature of GWI. PIs proposing studies using animal models should focus on long-term and latent effects of toxic exposures to closely represent the current status of GWI patients.NOTE: The 2008 report of the Research Advisory Committee on Gulf War Veterans� Illnesses, Gulf War Illness and the Health of Gulf War Veterans, provides information on GWI case definitions (pp. 29-30, p. 57), previous treatment research in Gulf War veterans (pp. 36-39), and treatment research related to other multi-symptom conditions (pp. 285-287). The report can be found online at: http://www1.va.gov/RAC-GWVI/.Research involving human subjects is permitted under this funding opportunity, but is restricted to studies without clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. For more information on clinical research, a Human Subject Resource Document is provided at https://cdmrp.org/Program_Announcements_and_Forms/.PIs wishing to apply for funding for a clinical trial should utilize either the Innovative Treatment Evaluation Award or the Clinical Trial Award mechanisms (for information about those mechanisms, see http://cdmrp.army.mil/gwirp). Refer to the General Application Instructions, Appendix 5, for helpful information about distinguishing clinical trials and clinical research. Retrospective studies or other non-interventional designs are acceptable under the IIRA award mechanism. Studies whose principal focus is on psychiatric disease or psychological stress as the primary cause of GWI will not be funded under this Program Announcement/Funding Opportunity.While Gulf War veterans are affected by Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig�s disease) at twice the rate of veterans who did not serve in the Gulf War, the GWIRP will not accept proposals focusing on ALS research. However, proposals that focus on GWI symptomatology may include GW veterans with ALS if the latter disorder is included in the study’s GWI case definition. The Office of the Congressionally Directed Medical Research Programs (CDMRP) has offered a separate ALS Research Program (see http://cdmrp.army.mil/alsrp). |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
301-682-5507
Email:help@cdmrp.org |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-11-GWIRP-IIRA |
| Funding Opportunity Title: | DoD Gulf War Illness Investigator-Initiated Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Apr 28, 2011 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Aug 25, 2011 |
| Archive Date: | Sep 24, 2011 |
| Estimated Total Program Funding: | $1,920,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The GWIRP Investigator-Initiated Research Award (IIRA) mechanism was first offered in FY06. Since then, 94 IIRA applications have been received, and 29 have been recommended for funding. The IIRA supports research focusing on the complex of symptoms known as Gulf War Illness (GWI), improving its definition and diagnosis, characterizing disease symptoms, and better understanding its pathobiology. It is intended to encourage basic or clinical developmental research aimed at identification of objective measures to distinguish ill from healthy veterans (e.g., biomarkers) or elucidate potential treatment targets for GWI. In addition, studies that characterize chronic effects of neurotoxic exposures at dosage comparable to that encountered during the Gulf War are acceptable. The IIRA provides investigators a mechanism to establish proof of principle for further development in future studies. Particular areas of interest include research on objective indicators of biological processes, or abnormalities in GWI associated with: � Central nervous system structure and function, in particular, the role of glial cells, astrocytes, and microglia in GWI symptomatology � Central neuroinflammatory processes � Autonomic nervous system function � Neuroendocrine measures � Immune parameters/Indicators of chronic infection � Gastrointestinal complaints/symptoms � Genetic, genomic, proteomic, or metabolic characteristics � Respiratory symptoms � Sexual dysfunction The IIRA is designed to promote new ideas in GWI research. Proposals are not required to include preliminary data; however, preliminary data may be used to support the objectives of a proposal. These data are not required to have come from the GWI research field. Proposals not supported by preliminary data should be based on a sound scientific rationale and may reflect clinical observations or seek to evaluate GWI discoveries made in relation to other chronic multi-symptom illnesses. Using either approach, however, the focus should be clearly on ill Gulf War veterans. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the project�s potential impact on GWI. PIs proposing clinical research must provide a published case definition they intend to use to define their GWI population. Any case definition must recognize the multi-symptom nature of GWI. PIs proposing studies using animal models should focus on long-term and latent effects of toxic exposures to closely represent the current status of GWI patients. NOTE: The 2008 report of the Research Advisory Committee on Gulf War Veterans� Illnesses, Gulf War Illness and the Health of Gulf War Veterans, provides information on GWI case definitions (pp. 29-30, p. 57), previous treatment research in Gulf War veterans (pp. 36-39), and treatment research related to other multi-symptom conditions (pp. 285-287). The report can be found online at: http://www1.va.gov/RAC-GWVI/. Research involving human subjects is permitted under this funding opportunity, but is restricted to studies without clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. For more information on clinical research, a Human Subject Resource Document is provided at https://cdmrp.org/Program_Announcements_and_Forms/. PIs wishing to apply for funding for a clinical trial should utilize either the Innovative Treatment Evaluation Award or the Clinical Trial Award mechanisms (for information about those mechanisms, see http://cdmrp.army.mil/gwirp). Refer to the General Application Instructions, Appendix 5, for helpful information about distinguishing clinical trials and clinical research. Retrospective studies or other non-interventional designs are acceptable under the IIRA award mechanism. Studies whose principal focus is on psychiatric disease or psychological stress as the primary cause of GWI will not be funded under this Program Announcement/Funding Opportunity. While Gulf War veterans are affected by Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig�s disease) at twice the rate of veterans who did not serve in the Gulf War, the GWIRP will not accept proposals focusing on ALS research. However, proposals that focus on GWI symptomatology may include GW veterans with ALS if the latter disorder is included in the study’s GWI case definition. The Office of the Congressionally Directed Medical Research Programs (CDMRP) has offered a separate ALS Research Program (see http://cdmrp.army.mil/alsrp). |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
301-682-5507
Email:help@cdmrp.org |
Related Documents
Folder 90053 Full Announcement-1 -> gwirp_fy11 iira pa_gg.pdf
Packages
| Agency Contact Information: | 301-682-5507 Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00050290 | Apr 27, 2011 | Aug 24, 2011 | View |
Package 1
Mandatory forms
90053 RR_SF424_1_2-1.2.pdf
90053 PerformanceSite_1_4-1.4.pdf
90053 RR_Budget-1.1.pdf
90053 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
90053 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
